Mostrar el registro sencillo del ítem
dc.contributor.author | Ferrandiz-Avellano, Maria-Jose | |
dc.contributor.author | Martin-Galiano, Antonio Javier | |
dc.contributor.author | Arnanz, Cristina | |
dc.contributor.author | Zimmerman, T | |
dc.contributor.author | de la Campa, Adela G | |
dc.date.accessioned | 2019-11-14T11:31:04Z | |
dc.date.available | 2019-11-14T11:31:04Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Antimicrob Agents Chemother. 2016;60(1):409-17. | es_ES |
dc.identifier.issn | 0066-4804 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/8594 | |
dc.description.abstract | We studied the transcriptomic response of Streptococcus pneumoniae to the fluoroquinolone moxifloxacin at a concentration that inhibits DNA gyrase. Treatment of the wild-type strain R6, at a concentration of 10× the MIC, triggered a response involving 132 genes after 30 min of treatment. Genes from several metabolic pathways involved in the production of pyruvate were upregulated. These included 3 glycolytic enzymes, which ultimately convert fructose 6-phosphate to pyruvate, and 2 enzymes that funnel phosphate sugars into the glycolytic pathway. In addition, acetyl coenzyme A (acetyl-CoA) carboxylase was downregulated, likely leading to an increase in acetyl-CoA. When coupled with an upregulation in formate acetyltransferase, an increase in acetyl-CoA would raise the production of pyruvate. Since pyruvate is converted by pyruvate oxidase (SpxB) into hydrogen peroxide (H2O2), an increase in pyruvate would augment intracellular H2O2. Here, we confirm a 21-fold increase in the production of H2O2 and a 55-fold increase in the amount of hydroxyl radical in cultures treated during 4 h with moxifloxacin. This increase in hydroxyl radical through the Fenton reaction would damage DNA, lipids, and proteins. These reactive oxygen species contributed to the lethality of the drug, a conclusion supported by the observed protective effects of an SpxB deletion. These results support the model whereby fluoroquinolones cause redox alterations. The transcriptional response of S. pneumoniae to moxifloxacin is compared with the response to levofloxacin, an inhibitor of topoisomerase IV. Levofloxacin triggers the transcriptional activation of iron transport genes and also enhances the Fenton reaction. | es_ES |
dc.description.sponsorship | This study was supported by grants BIO2011-25343 and BIO2014-55462-R from Plan Nacional de I+D+I of the Ministry of Economy and Competitiveness. A.J.M.-G. is the recipient of a Miguel Servet contract from the Spanish Ministry of Economy and Competitiveness. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Society for Microbiology (ASM) | es_ES |
dc.type.hasVersion | AM | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Acetyl-CoA Carboxylase | es_ES |
dc.subject.mesh | Acetyltransferases | es_ES |
dc.subject.mesh | Anti-Bacterial Agents | es_ES |
dc.subject.mesh | Bacterial Proteins | es_ES |
dc.subject.mesh | DNA Topoisomerase IV | es_ES |
dc.subject.mesh | Drug Resistance, Multiple, Bacterial | es_ES |
dc.subject.mesh | Fluoroquinolones | es_ES |
dc.subject.mesh | Fructosephosphates | es_ES |
dc.subject.mesh | Gene Deletion | es_ES |
dc.subject.mesh | Gene Expression Profiling | es_ES |
dc.subject.mesh | Gene Ontology | es_ES |
dc.subject.mesh | Glycolysis | es_ES |
dc.subject.mesh | Hydrogen Peroxide | es_ES |
dc.subject.mesh | Iron | es_ES |
dc.subject.mesh | Levofloxacin | es_ES |
dc.subject.mesh | Microbial Sensitivity Tests | es_ES |
dc.subject.mesh | Molecular Sequence Annotation | es_ES |
dc.subject.mesh | Moxifloxacin | es_ES |
dc.subject.mesh | Oxidative Stress | es_ES |
dc.subject.mesh | Pyruvate Oxidase | es_ES |
dc.subject.mesh | Pyruvic Acid | es_ES |
dc.subject.mesh | Streptococcus pneumoniae | es_ES |
dc.subject.mesh | Transcription, Genetic | es_ES |
dc.subject.mesh | Gene Expression Regulation, Bacterial | es_ES |
dc.title | Reactive Oxygen Species Contribute to the Bactericidal Effects of the Fluoroquinolone Moxifloxacin in Streptococcus pneumoniae | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 26525786 | es_ES |
dc.format.volume | 60 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 409-417 | es_ES |
dc.identifier.doi | 10.1128/AAC.02299-15 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1098-6596 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1128/AAC.02299-15 | es_ES |
dc.identifier.journal | Antimicrobial agents and chemotherapy | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/BIO2011-25343 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/BIO2014-55462-R | es_ES |
dc.rights.accessRights | open access | es_ES |